News
US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on
Curadigm announces the selection of its Nanoprimer technology by the National Cancer Institute for a characterization & development collaboration
Regulatory News:
Curadigm, an early-stage nanotechnology company committed to improving treatment outcomes by redefining the therapeutic balance between bioavailability, toxicity, and efficacy
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Aurinia Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the fourth quarter and year ended December 31, 2019. Amounts, unless
Savara to Report Fourth Quarter/Year-End 2019 Financial Results and Provide Business Update
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report fourth quarter/year-end 2019 financial results and provide a business update on Thursday
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on
Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on
Navidea Biopharmaceuticals to Host Fourth Quarter 2019 Earnings Conference Call and Corporate Update
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Biofrontera: Kleiner, aber feiner Geldregen
Die Biofrontera-Aktie (WKN: 604611) gehört am Dienstag zu den stärksten Werten. Im Xetra-Handel schließt der Kurs +16,10% höher bei 4,65 Euro. Das hat einen guten Grund.
Das Biopharma-Unternehmen
Clovis Oncology to Present at the Barclays Global Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Barclays Global Healthcare Conference on Tuesday, March
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results on March 5, 2020
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its fourth quarter and full year 2019 financial results on Thursday, March 5, 2020, after
Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB
Takeda schließt Verkauf ausgewählter OTC- und nicht zum Kerngeschäft gehörender Assets an Acino ab
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda“) meldete heute den Abschluss des bereits angekündigten Verkaufs eines Portfolios ausgewählter, frei verkäuflicher
Takeda vereinbart Veräußerung ausgewählter kernferner und OTC-Aktiva in Lateinamerika an Hypera Pharma für 825 Mio. USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda“) hat eine Vereinbarung darüber geschlossen, ein Portfolio ausgewählter kernferner Produkte ausschließlich für den
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
-
Cowen 40th Annual Health Care
Takeda Completes Sale of Select OTC and Non-Core Assets to Acino
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription
Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin
Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Spain
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca® (rucaparib) is now available and reimbursed in Spain following the Spanish Interministerial Commission on Prices of Medicines and
Nanobiotix 2019 Q4 and Annual Revenues
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of
Puma Biotechnology to Present at Cowen’s Annual Health Care Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
Sangamo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2019 financial results and recent business highlights.
“This quarter marked an
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases
Biogen Inc. (Nasdaq: BIIB) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a global licensing collaboration agreement to develop
Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for neratinib in
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and full year 2019 financial results before
Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on